Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...
With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...
Cancer is becoming a global crisis shaped less by biology than by inequality, risk exposure, and access to care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback